Vir Biotechnology, Inc. reports results for the quarter ended June 30 - Earnings Summary

Vir Biotechnology

06/08/2026 24:43

Vir Biotechnology, Inc. VIR.OQ reported quarterly adjusted earnings of 47 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -80 cents.  The mean expectation of ten analysts for the quarter was for earnings of 33 cents per share. Wall Street expected results to range from -87 cents to $1.45 per share.
Revenue rose 19,582.5% to $238.95 million from a year ago; analysts expected $216.46 million. 
Vir Biotechnology, Inc.'s reported EPS for the quarter was 47 cents​.
The company reported quarterly net income of $80.08 million.
Vir Biotechnology, Inc. shares had fallen by 10.0% this quarter and gained 52.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 338% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Vir Biotechnology, Inc. is $21.00, about 56.6% above its last closing price of $9.11
This summary was machine generated from LSEG data August 5 at 11:43 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.33
0.47
Beat
Mar. 31 2026 
-0.10
-0.85
Missed
Dec. 31 2025 
-0.49
-0.31
Beat
Sep. 30 2025 
-0.85
-1.17
Missed